Consumer Law LibrarySearchBy decadeBy respondentBy topicBy outcomeDataAbout

Imperial Drug Exchange, Inc

Volume 38 · 38 F.T.C. 440

Citation
38 F.T.C. 440
Docket
5094
Complaint
1943-12-09
Decision
1944-05-09
Document type
final order
Case type
consumer protection
Statutes
FTC Act (section 5)
Industry
Medicinal preparations industry
Outcome
cease and desist
Relief
cease_and_desist; affirmative_disclosure; compliance_reporting
Commission counsel
lVilliarn L. 'l'aggart
Source
Original volume PDF
Original PDF
This decision as a PDF

deceptive advertisinghealth claims

Cite this decision

Imperial Drug Exchange, Inc, 38 F.T.C. 440 (1944). Consumer Law Library, https://consumerlawlibrary.org/decisions/v038-0050

Report an error in this record (decision id v038-0050)

Order status: presumptively_terminable_pre_1995. Sunset may be extended by the latest qualifying federal-court complaint alleging an order violation; complaints, dismissal/appeal outcomes, and respondent-specific extensions are not fully tracked.

Cited by 0 later FTC decisions

Cites

Text (OCR of the scan at left; may contain errors)

IN THE MATTER OF 11\IPERIAL DRUG EXCHANGE, INC., ALSO TRADING AS DUPREE MEDICAL COMPANY, AND ABRAHAlVI PARODNEY COMPLAINT, FINDINGS, AND ORDER IN REGARD TO THE ALLEGED VIOLATION OF SEC. I> OF AN ACT OF CONGRESS APPROVED SEPT, 26, 1914 Docket 5094. Complaint, Dec. 9, 1943-Decision, May 9, 1944 Where a corporation and its president, engaged in the interstate sale and distribution of its "Dupree Brand New Formula Pills" and "Dupree Pills, Double Strength, New and Improved Formula"; in advertisements thereof which it disseminated through the mails and to dealers who distributed them among the purchasing public- (a) Falsely represented that their said preparations constituted a competent and effective treatment for delayed menstruation arising from colds, nervous strain, poor nutrition, anemia, fright, over-exposure; inadequate clothing, and change of climate; and (b) Failed to reveai facts material in the light of such representations or material with respect to the consequences which might result from the use of said preparations under prescribed or usual condition, in that they were irritant laxatives and as such potentially dangerous when taken by persons suffering from abdominal pain, nausea, vomiting or other symptoms of appendicitis; With result that said advertising matter, disseminated by dealers, served as instrumentalities through which members of the purchasing public were deceived and misled as to the therapeutic value and safety of their said preparations, whereby such public was induced to purchase substantial quantities thereof: lleld, That said acts and practices, under the circumstances set forth, were all to the prejudice and injury of the public, and constituted unfair and deceptive acts and practices in commerce.

Mr. lVilliarn L. 'taggart for the Commission. COMPLAINT ' Pursuant to the provisions of the Federal Trade Commission Act, and by virtue of the authority vested in it by said act, the Federal Trade Commission having reason to believe that Imperial Drug Exchange, In.c., a corporation, Imperial Drug Exchange, Inc., a C?rporation, trading as Dupree Medical Company and Abraham Parodney, individually, and as an officer of Imperial Drug Exchange, Inc., a corporation, herein referred to as respondents, have violated the provisions of said act, and it appearing to the Commission that a proceeding by it in respect thereof would be in the public interest, hereby issues its complaint, stating its charges in that respect as follows:

PARAGRAPH 1. Imperial Drug Exchange, Inc., is a corporation, chartered and doing business under the laws of the State of New York with its principal place of business located at 20 East 17th Street, New York, N. Y. Said corporation trades and carries on certain of its business under the name of Dupree lVIedical Company, particularly that part of its business referred to in this complaint.

Abraham Parodney, is an individual, and is President, of the corporate respondent, Imperial Drug Exchange, Inc. This individual respondent IMPERIAL DRUG EXCHANGE, INC. ET AL. 441 440 Complaint directs and controls the policies and practices of the respondent corporation including its business carried on as Dupree Medical Company .. The address of said individual respondent is 20 East 17th St., New York, N.Y. PAR. 2. Respondents are now, and for more than one year last past have been, engaged in the sale and distribution of certain medicinal preparations designated as:

Dupree Brand New Formula Pills and Dupree Pills, Double Strength, New and Improved Formula. Respondents cause said preparations, when sold, to be transported from their place of business in the State of New York to purchasers thereof . located in various other States of the United States and in the District of Columbia. Respondents. maintain, and at all times mentioned herein have maintained, a course ... of trade in their preparations in commerce between and among the various States of the United States and in the District of Columbia.

PAR. 3. In the course and conduct of their aforesaid business, the respondents have disseminated and are now disseminating, and have· caused and are now causing the dissemination of, false advertisements concerning their said preparations by the United States Mail and by various other means in commerce, as commerce is defined in the Federal Trade Commission Act; and respondents have also disseminated and are now disseminating, and have caused and are now causing the dissemination of, false advertisements concerning their said preparations by various means, for the purpose of inducing and which are likely to induce, directly or indirectly, the purchase of said preparations in commerce, as commerce is defined in the Federal Trade Commission Act. Respondents also cause such false advertising to be transported by means of the United States mails and by other means in commerce, to wholesale and retail dealers of their products. Who.lesale dealers cause such material to be transported to retailers and retailers distribute the same among the purchasing public.

Among and typical of the false, misleading and deceptive statements and representations contained in said false advertisements disseminated and caused to be disseminated as hereinabove set forth, by the United States mails, and by means of circulars and other advertising literature, are the following: · ' Dupree Pills have been used throughout the country by women who have found them effective in delayed menstruation due to colds and nervous strain. · The phenomenon of menstruation which appears ab·out every 28 days is a natural function which may be disturbed by a number of causes, such as poor nutrition, apemia, fright, colds, over-exposure, (inadequate clothing, and change of climate). · It is for delayed menstruation due to these causes only, that Dupree Pills are recommended.

Dupree Double Strength Pills may be taken for the same conditions as the Dupree Single Strength Pills, but are sold for use in cases which require a stronger medication PAn. 4. Through the use of the foregoing statements and representations and others of similar import not specifically set out herein, the respondents represent and have represented, that their preparations designated as "Dupree Brand New Formula Pills" and "Dupree Pills, Double Strength, New and Improved Formula," constitute a competent and effective treatment for delayed menstruation arising from colds, nervous 691546"'-46-vol. 38--31 Findings 38F. T. C.

strain, poor nutrition, anemia, fright, over-exposure, inadequate clothing, and change of climate.

PAR. 5. The foregoing. representations are grossly exaggerated, false and misleading. In truth and in fact, respondents' preparations are not a competent and effective treatment for delayed menstruation arising from nervous strain, poor .nutrition, anemia, fright, colds and troubles caused by over-exposure, inadequate clothing, change of climate, or from any other cause.

PAR. 6. Respondents advertisements disseminated as aforesaid, constitute false advertising for the further reason that they fail to reveal facts material in the light of such representations or material with respect to consequences which may result from the use of the preparations to which the advertisements relate, under the· conditions prescribed in said advertisements or under such conditions as are cust.omary or usual. In truth and in fact the said preparations arc irritant laxatives and are potentially dangerous when taken by persons suffering from abdominal pains, stomach ache,· cramps, colic, nausea, vomiting or other symptoms of appendicitis.

PAR. 7. The circulars and advertising matter placed in the hands of wholesalers and retailers and distributed and disseminated by them serve as instrumentalities by and through which members of the purchasing public may be and are likely to be deceived and misled as to the therapeutic value and safety of respondents' preparations. PAR. 8. The use by the respondents of the aforesaid false, misleading and deceptive statements and repres<:ntations with respect to their said preparations, disseminated as aforesaid, has had, and now has, the capacity and tendency to mislead and deceive a substantial portion of the purchasing public into the erroneous and mistaken belief that respondents' preparations possess properties which they do not in fact possess, and that said preparations are in all cases safe and harmless, when such is not the fact. As a result of such erroneous and mistaken belief the purchasing public has been inducedto purchase and has purchased substantial quantities of respondents' preparations.

PAR. 9. The aforesaid acts and practices of the respondents, as herein . alleged, are all to the prejudice and injury of the public and constitute unfair and deceptive acts and practices in commerce within the intent and meaning of the Federal Trade Commission Act.

REPORT, FINDINGS As TO THE Facts, AND Onder Pursuant to the provisions of the Federal Trade Commission Act, the Federal Trade Commission, on the 9th day of December, 1943, issued and subsequently served its complaint in this proceeding upon respondents, Imperial Drug Exchange, Inc., a corporation, also trading as Dupree Medical Company, and Abraham Parodncy, individually, and as an officer, of Imperial Drug Exchange, Inc., charging them with the use of unfair and deceptive acts and practices in commerce in violation of the provisions of said act. On March 171 19'14, the respondents filed their answer, in which answer they admitted all the material allegations of fact set forth in said complaint and waived all intervening procedure and further hearing as to said facts. Thereafter, the proceeding regularly came on for final hearing before the Commission on the said complaint and the answer thereto, and the Commission, having duly considered the matter IMPERIAL DRUG EXCHANGE, INC. ET AL. 443 440 Findings and being now fully advised in the premises, finds that this proceeding is in the interest of the public and makes this its findings as to the facts and its conclusion drawn theref1:om.

FINDINGS AS TO THE FACTS PARAGRAPH 1. Respondent, Imperial Drug Exchange, Inc., is a corporation, chartered and doing business under the laws of the State of New York, with its principal place of business located at 20 East 17th Street, New York, N.Y. Said corporation trades and carries on certain of its business under the name of Dupree Medical Company, particularly that part of its business referred to herein.

Respondent, Abraham Parodney, is an individual, and is president of the corporate respondent, Imperial Drug Exchange, Inc. This individual respondent directs and controls the policies and practices of the respondent corporation, including its business carried on as Dupree Medical Company. The address of said individual respondent is 20 East 17th Street, New York, N.Y. · PAR. 2. Respondents are now, and for more than one year last past have been, engaged in the sale and distribution of certain medicinal prep~ arations designated as "Dupree Brand New Formula Pills" and "Dupree Pills, Double Strength, New and Improved Formula." Respondents cause said preparations, when sold, to be transported from their place of business in the State of New York to purchasers thereof located in various other States of the United States and in the District of Columbia. Respondents maintain, and at all times mentioned herein have maintained, a course of trade in their preparations in commerce between and among the various States of the United States and in the District of Columbia. · PAR. 3. In the course and conduct of their aforesaid business, the respondents have disseminated and are' now disseminating,. and have caused and are now causing the dissemination of, false advertisements concerning their said preparations by the United States mail and by various other means in commerce, as "commerce" is defined in the Federal Trade Commission Act; and respondents have also disseminated and are now disseminating, and have caused and are now causing the dissemination of, false advertisements concerning their said preparations by various means, for the purpose of inducing and which are likely to induce, directly or indirectly, the purchase of said preparations in commerce, as "commerce" is defined in the Federal Trade Commission Act. Respondents also cause such false advertising to be transported by means of the United States mails and by other means in commerce to wholesal~ and retail dealers in their products. Wholesale dealers cause such material to be transported to retailers, and retailers distribute the same among the purchasing public.

Among and typical of the false, misleading, and deceptive statements and representations contained in said false advertisements disseminated and caused to be disseminated as hereinabove set forth, by the United States mails and by means of circulars and other advertising literature, arc the following:

Dupree Pills have been used throughout the country by women who have found them effective in delayed menstruation due to colds and nervous strain. Conclusion 38 F. T. C.

The phenomenon of menstruation which appears about every 28 days is a natural function which may be disturbed by a number of causes, such as poor nutrition, anemia, fright, colds, overexposure (Inadequate clothing, anq change_of climate). It is for delayed menstruation due to these causes only, that Dupree Pills are recommended.

Dupree Double Strength Pills may be taken for the same conditions as the Dupree Single Strength~ Pills, but are sold for use in cases which require a stronger medication. PAR. 4. Through the use of the foregoing statements and representations and others of similar import not specifically set out herein, the respondents represent and have represented that their preparations designated as "Dupree Brand New Formula Pills" and "Dupree Pills, Double Strength, New and Improved Formula" constitute a competent and effective treatment for delayed menstruation arising from colds, nervous strain, poor nutrition, anemia, fright, overexposure, inadequate clothing, . and change of climate.

PAR. 5. The foregoing representations are grossly exaggerated, false, and misleading. In truth and in fact, respondents' preparations are not a competent and effective treatment for delayed menstruation arising from colds, nervous strain, poor nutrition, anemia, fright, overexposure, inadequate clothing, change of climate, or from any other cause. PAR. 6. Respondents' advertisements, disseminated as aforesaid, constitute false advertising for the further reason that they fail to reveal facts material in the light of such representations, or material with respect to consequences which may result from the use of the preparations to which the advertisements relate under the conditions prescribed in said advertisements or under such conditions as are customary or usual. In truth and in fact, the said preparations are irritant laxatives and are potentially dangerous when taken by persons suffering from abdominal pains, nausea, vomiting, or other symptoms of appendicitis. PAR. 7. The circulars and advertising matter placed in the hands of wholesaler~ and retailers, and distributed and disseminated by them, serve as instrumentalities by and through which members of the purchasing public may be and are likely to be deceived and misled as to the therapeutic value and safety of respondents' preparations. PAR. 8. The use by the respondents of the aforesaid false, misleading, and deceptive statements and representations with respect to their said preparations, disseminated as aforesaid, has had and now has the capacity and tendency to mislead and deceive a substantial portion of the purchasing public into the erroneous and mistaken belief that respondents' preparations possess properties which they do not in fact possess, and that said preparations are in all cases safe and harmless when such is not' the fact. A,~ a result of such erroneous and mistaken belief, the purchasing public has been induced to purchase and has purchased substantial quantities of respondents' preparations. CONCLUSION The aforesaid acts and practices of the respondents, as herein found, are all to the prejudice and injury of the public, and constitute unfair and deceptive acts and practices in commerce within the intent and meaning of the Federal Trade Commission Act.

IMPERIAL DRUG EXCHANGE, INC. ET AL. 445 440 Order ORDER TO CEASE AND DESIST · This proceeding having been heard by the Federal Trade Commission on the complaint of the Commission and the answer of respondents, in which answer respondents admit all the material allegations of fact set forth in said complaint and state that they waive all intervening procedure and further hearing as to said facts, and the Commission having made its findings as to the facts and its conclusion that said respondents have violated the provisions of the Federal Trade Commission"Act. It is ordered, That the respondents, Imperial Drug Exchange, Inc., a corporation, also trading as Dupree Medical Company, or trading under any other name, its officers, and Abraham Parodney, individually, and as an officer, of said corporation, and respondents' representatives, agents, and employees, directly or through any corporate or other device, in connection with the offering for sale, sale, or distribution of respondents' medicinal preparations designated "Dupree Brand New Formula Pills" land "Dupree Pills, Double Strength, New and Improved Formula," or any other medicinal preparations composed of substantially similar ingredients or possessing substantially similar properties, whether sold under the same names or any other name or names, do forthwith cease and desist from directly or indirectly:

1. Disseminating or causing to be di~seminated any advertisement by means of the United States mails, or by any means in commerce, as '1 commerce" is defined in the Federal Trade Commission Act. which advertisement represents, directly or by implication, that· said preparations constitute competent and effective treatments for delayed menstruation arising from colds, nervous strain, poor nutrition, anemia, fright, overexposure, inadequate clothing, change of climate, or from any other cause, or which advertisement fails to reveal that said preparations should not be used in the presence of abdominal pains, nausea, vomiting, or other symptoms of appendicitis; provided, however, that such advertisement need contain only the statement, "CAUTION: Use Only as Directed," if and when the directions for use, wherever they appear, on the label, in the labeling, or both on the label and in the labeling, contain a warning to the above effect.

2. Disseminating or causing to be disseminated any advertisement by any means for the purpose of inducing, or which is likely to induce, directly or indirectly, the purchase of said preparations in commerce, as "commerce" is defined in the Federal Trade Commission Act, which advertisement contains any representation prohibited in paragraph 1 hereof, or which fails to comply with the affirmative requirements set forth in paragraph 1 hereof. . It is further ordered, That the respondents shall, within 60 days after service upon them of this order, file with the Commission a report in writing, setting forth in detail the manner and form in which they have complied with this order.

446 Federal TRAD:in COMMISSION DECtS!ONS Complaint 38 F. T. C.

← 38 F.T.C. 433 · 38 F.T.C. 446 →